TIDMMEDG 
 
 
Medgenics Inc 
27 January 2010 
 
 
 
 
 
 
 
NEW PATENT APPROVAL BOOSTS INTELLECTUAL PROPERTY PORTFOLIO AT MEDGENICS 
 
 
 
 
Misgav, Israel and London, UK - 27 January 2010 - Medgenics (AIM: MEDG and 
MEDU), the biopharmaceutical company that creates therapeutic protein producing 
implantable Biopumps announced today that the Japanese Patent Office has 
approved patent application number 2003-550677 titled CLOSED AUTOMATED SYSTEMS 
FOR TISSUE BASED THERAPY DOSING AND ADMINISTRATION OF SAME. This strengthens the 
suite of over 60 approved patents and patent applications owned and licensed by 
the company which cover all aspects of the company's technology for producing 
autologous Biopumps that are capable of producing a wide range of therapeutic 
proteins when implanted into humans. 
 
 
Dr. Andrew Pearlman, CEO of Medgenics commented: 
"The granting of additional patents is always very important to a technology 
driven company such as Medgenics. We now have issued or applied for patents in 
all major jurisdictions covering key aspects of our platform technology for 
obtaining micro-organs from a patient's tissue, processing them to produce 
therapeutic proteins and then reinserting them into the patient to provide 
continuous delivery of therapeutic proteins over an extended period of time". 
 
 
For further information contact: 
 
 
+----------------------------------------+-----------------------------+ 
| Medgenics, Inc.                        | Phone: +972 4 902           | 
| Dr. Andrew L. Pearlman                 | 8900                        | 
|                                        |                             | 
+----------------------------------------+-----------------------------+ 
| De Facto Communications                | Phone: +44 20               | 
| Mike Wort                              | 7861 3838                   | 
| Anna Dunphy                            | m.wort@defacto.com          | 
|                                        | a.dunphy@defacto.com        | 
+----------------------------------------+-----------------------------+ 
| Grayling (Investor Relations - US)     | Phone: +1 646 284           | 
| Leslie Wolf-Creutzfeldt                | 9472                        | 
|                                        | lwolf-creutzfeldt@hfgcg.com | 
+----------------------------------------+-----------------------------+ 
| Blomfield Corporate Finance Limited    | Phone: +44 207 489          | 
| (Nominated Adviser)                    | 4500                        | 
| James Pinner                           |                             | 
| Alan MacKenzie                         |                             | 
|                                        |                             | 
+----------------------------------------+-----------------------------+ 
| SVS Securities plc (Broker)            | Phone: +44 207 638          | 
| Ian Callaway                           | 5600                        | 
|                                        |                             | 
+----------------------------------------+-----------------------------+ 
 
 
 
 
About Medgenics: 
Medgenics is a clinical-stage biopharmaceutical company developing its unique 
tissue-based Biopump platform technology to provide sustained-action protein 
therapy for the treatment of a range of chronic diseases. The Company currently 
has three products in development based on this technology and addressing the 
indications of: 
 
 - Anemia - using EPODURE, a Biopump producing erythropoietin (EPO) 
- Hepatitis-C - using INFRADURE - a Biopump producing interferon-alpha (IFN-a) 
- Hemophilia - using a Biopump to produce clotting Factor VIII 
The Company's Phase I/II clinical trial using EPODURE to treat anemia in 
patients with chronic kidney disease, has demonstrated proof of concept of the 
Biopump. Designed to produce and deliver a therapeutic dose of EPO steadily for 
six months or more, EPODURE Biopumps have already provided effective anemia 
treatment in most of these patients for 6-12 months, even at the low 
administered dose. 
Medgenics intends to develop its innovative products and bring them to market 
via multiple strategic partnerships with major pharmaceutical and/or medical 
device companies. In addition to treatments for Anemia, Hepatitis-C, Hemophilia, 
Medgenics plans to develop and/or out-license a pipeline of future Biopump 
products targeting the large and rapidly growing global protein therapy market, 
which is forecast to reach US $87 billion by 2010. Other potential applications 
of Biopumps producing various proteins include multiple sclerosis, arthritis, 
pediatric growth hormone deficiency, obesity, and diabetes. 
 
 
 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NRAGIGDBSUDBGGR
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Medgenics(Regs) Charts.
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Medgenics(Regs) Charts.